EMA will accept biosimilar reference products sourced outside EEA, but not immediately
This article was originally published in SRA
Executive Summary
The European Medicines Agency has issued an update to its procedural advice document EMA/940451/2011 that confirms that the agency, with regard to biosimilar applications under the centralised procedure, will accept batches of reference medicinal products sourced from outside the European Economic Area in certain pre-clinical and clinical studies for the comparability exercise1. The change will not happen immediately, however.
You may also be interested in...
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.
AZ Secures EU Fast-Tack Review For Nirsevimab
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.